

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/542,501
				Filing Date	January 15, 2004
				First Named Inventor	Ronald W. Wood
				Art Unit	1614
				Examiner Name	Brian-Yong S. Kwon
Sheet	1	of	4	Attorney Docket Number	176/61373 (1177)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	RE39,820 E	09/04/2007	BANHOLZER et al.	
	2.	2,648,667	08/11/1953	STERNBACH	
	3.	4,467,095	08/21/1994	TREVES et al.	
	4.	6,482,837 B1	11/19/2002	WOOD	
	5.	6,696,462	02/24/2004	EICKMEIER et al.	

U.S. PUBLISHED PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴			
	6.	WO	98/00133	01/08/1998	FABIANO et al.	
	7.	WO	98/00138	01/08/1998	FABIANO et al.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	8.	ABOOD, "The Psychotomimetic Glycolate Esters," in Burger, ed., <i>Drugs Affecting the Central Nervous System</i> Vol. 2, Chapter 4, New York: Marcel Dekker, Inc., pp. 127-167 (1968)	
	9.	ABOOD, "Anticholinergics," Chap 15 in <i>Psychotropic Agents, Part III: Alcohol and Psychomimetics, Psychotropic Effects of Central Acting Drugs</i> , F. Hoffmeister et al., eds., Springer-Verlag, Berlin pp. 331-347 (1982)	
	10.	BAUMGOLD et al., "Chemical Factors Influencing the Psychotomimetic Potency of Glycolate Esters," <i>Life Sciences</i> 17:603-612 (1975)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/542,501
				Filing Date	January 15, 2004
				First Named Inventor	Ronald W. Wood
				Art Unit	1614
				Examiner Name	Brian-Yong S. Kwon
Sheet	2	of	4	Attorney Docket Number	176/61373 (1177)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	11.	BAUMGOLD et al., "Studies on the Relationship of Binding Affinity to Psychoactive and Anticholinergic Potency of a Group of Psychotomimetic Glycolates," <i>Brain Research</i> 124:331-340 (1977)		
	12.	BONNER et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes," <i>Science</i> 237:527-532, Erratum 1556, 1628 (1987)		
	13.	BONNER et al., "Cloning and Expression of the Human and Rat m5 Muscarinic Acetylcholine Receptor Genes," <i>Neuron</i> 1:403-410 (1988)		
	14.	BROWN, "Atropine, Scopolamine, and Related Antimuscarinic Drugs," in Goodman et al., eds., <i>The Pharmacological Basis of Therapeutics</i> , Eighth Edition, New York: Macmillan Publishing Co., pp. 150-165 (1990)		
	15.	BUCKLEY et al., "Antagonist Binding Properties of Five Cloned Muscarinic Receptors Expressed in CHO-K1 Cells," <i>Molecular Pharmacology</i> 35:469-476 (1989)		
	16.	CARROLL et al., "Probes for the Cocaine Receptor. Potentially Irreversible Ligands for Dopamine Transporter," <i>J. Med. Chem.</i> 35:1813-1817 (1992)		
	17.	CARTER et al., Analogues of Oxybutynin. Synthesis and Antimuscarinic and Bladder Activity of Some Substituted 7-Amino-1-hydroxy-5-heptyn-2-ones and Related Compounds," <i>J. Med. Chem.</i> 34:3065-3074 (1991)		
	18.	CEREDA et al., "Synthesis and Biological Evaluation of New Antimuscarinic Compounds with Amidine Basic Centers. A Useful Bioisosteric Replacement of Classical Cationic Heads," <i>J. Med. Chem.</i> 33:2108-2113 (1990)		
	19.	COMER et al., "Clocinnamox: A Novel, Systemically-Active, Irreversible Opioid Antagonist," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 262(3):1051-1056 (1992)		
	20.	CONNOR et al., "Early Cystometrograms Can Predict the Response to Intravesical Instillation of Oxybutynin Chloride in Myelomeningocele Patients," <i>The Journal of Urology</i> 151:1045-1047 (1994)		
	21.	DAVIES et al., "Novel 2-Substituted Cocaine Analogs: Binding Properties at Dopamine Transport Sites in Rat Striatum," <i>European Journal of Pharmacology - Molecular Pharmacology Section</i> 244:93-97 (1993)		
	22.	DECKERS, "The Chemistry of New Derivatives of Tropane Alkaloids and the Pharmacokinetics of a New Quaternary Compound," <i>Postgraduate Medical Journal</i> 51(Suppl. 7):76-81 (1975)		
	23.	DELFORGE et al., "Noninvasive Quantification of Muscarinic Receptors In Vivo With Positron Emission Tomography in the Dog Heart," <i>Circulation</i> 82(4):1494-1504 (1990)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/542,501
				Filing Date	January 15, 2004
				First Named Inventor	Ronald W. Wood
				Art Unit	1614
				Examiner Name	Brian-Yong S. Kwon
Sheet	3	of	4	Attorney Docket Number	176/61373 (1177)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	24.	DELFORGE et al., "Quantification of Myocardial Muscarinic Receptors with PET in Humans," <i>The Journal of Nuclear Medicine</i> 34(6):981-991 (1993)		
	25.	EHLERT et al., "The Quaternary Transformation Products of N-(3-Chloropropyl)-4-Piperidinyl Diphenylacetate and N-(2-Chloroethyl)-4-Piperidinyl Diphenylacetate (4-DAMP Mustard) Have Differential Affinity for Subtypes of the Muscarinic Receptor," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 276(2):405-410 (1996)		
	26.	GIBSON et al., "The Distribution of the Muscarinic Acetylcholine Receptor Antagonists, Quinuclidinyl Benzilate and Quinuclidinyl Benzilate Methiodide (both tritiated), in Rat, Guinea Pig, and Rabbit," <i>The Journal of Nuclear Medicine</i> 20(8):865-870 (1979)		
	27.	GOLDSTEIN et al., "Principles of Drug Action: The Basis of Pharmacology," Second Edition, New York: John Wiley & Sons, pp. 22-32 (1974)		
	28.	GORDON et al., "Distance Geometry of α -Substituted 2,2-Diphenylpropionate Antimuscarinics," <i>Molecular Pharmacology</i> 36:766-772 (1989)		
	29.	GRIFFIN et al., "Kinetics of Activation and <i>In Vivo</i> Muscarinic Receptor Binding of N-(2-Bromoethyl)-4-Piperidinyl Diphenylacetate: An Analog of 4-DAMP Mustard," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 266(1):301-305 (1993)		
	30.	GROSS, "Medical Intelligence Drug Therapy. Ipratropium Bromide," <i>The New England Journal of Medicine</i> 319:486-494 (1988)		
	31.	GUAN et al., "A Minipig Model for Urodynamic Evaluation of Infravesical Obstruction and its Possible Reversibility," <i>The Journal of Urology</i> 154:580-586 (1995)		
	32.	HAEUSLER et al., "Drug Therapy of Urinary Urge Incontinence: A Systematic Review," <i>Obstetrics & Gynecology</i> 200(5):1003-16 (2002)		
	33.	KAISER et al., "Synthesis and Antimuscarinic Properties of Some N-Substituted 5-(Aminomethyl)-3,3-diphenyl-2(3H)-Furanones," <i>J. Med. Chem.</i> 35:4415-4424 (1992)		
	34.	KAISER et al., "Synthesis and Antimuscarinic Activity of Some 1-Cycloalkyl-1-Hydroxy-1-Phenyl-3-(4-Substituted Piperazinyl)-2-Propanones and Related Compounds," <i>J. Med. Chem.</i> 36:610-616 (1993)		
	35.	KONDO et al., "A Study on the Affinities of Various Muscarinic Antagonists to the Human Detrusor Muscle," <i>J. Smooth Muscle Res.</i> 29:63-68 (1993) (abstract in English)		
	36.	KONDO et al., "Muscarinic Cholinergic Receptor Subtypes in Human Detrusor Muscle Studied by Labeled and Nonlabeled Pirenzepine, AFDX-116 and 4DAMP," <i>Urol. Int.</i> 54:150-153 (1995)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/542,501
				Filing Date	January 15, 2004
				First Named Inventor	Ronald W. Wood
				Art Unit	1614
				Examiner Name	Brian-Yong S. Kwon
Sheet	4	of	4	Attorney Docket Number	176/61373 (1177)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	37.	KRISHNAN et al., "A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multicentre Study of Intravesical Oxybutynin," <i>Neurourol. & Urodynamics</i> 15:307-308 (1996) (Abstract #32)		
	38.	NEWBERRY et al., "Pharmacological Differences Between Two Muscarinic Responses of the Rat Superior Cervical Ganglion <i>In Vitro</i> ," <i>Br. J. Pharmac.</i> 92:817-826 (1987)		
	39.	NORDVALL et al., "Binding-Site Modeling of the Muscarinic m1 Receptor: A Combination of Homology-Based and Indirect Approaches," <i>J. Med. Chem.</i> 36:967-976 (1993)		
	40.	PARSONS et al., "Epithelial Dysfunction in Nonbacterial Cystitis (Interstitial Cystitis)," <i>The Journal of Urology</i> 145:732-735 (1991)		
	41.	PETERSON et al., "Mini-Pig Urinary Bladder Function: Comparisons of <i>In Vitro</i> Anticholinergic Responses and <i>In Vivo</i> Cystometry with Drugs Indicated for Urinary Incontinence," <i>J. Auton. Pharmac.</i> 10:65-73 (1990)		
	42.	ROBERTS et al., "A Pharmacological Study of the Responses Induced by Muscarinic Agonists on the Isolated Superior Cervical Ganglion of the Guinea Pig," <i>European Journal of Pharmacology</i> 186:257-265 (1990)		
	43.	RZESZOTARSKI et al., "Analogues of 3-Quinuclidinyl Benzilate," <i>J. Med. Chem.</i> 25:1103-1106 (1982)		
	44.	SEBASTIAN et al., "14 β -[(p-Nitrocinnamoyl)amino]morphinones, 14 β -[(p-Nitrocinnamoyl)amino]-7,8-dihydromorphinones, and Their Codeinone Analogues: Synthesis and Receptor Activity," <i>J. Med. Chem.</i> 36:3154-3160 (1993)		
	45.	SETHIA et al., "An Animal Model of Non-Obstructive Bladder Instability," <i>The Journal of Urology</i> 143:1243-1246 (1990)		
	46.	SHISHIDO et al., "Muscarinic Receptor Subtypes and Their Functional Roles in Rat Detrusor Muscle," 26 th Meeting of the International Continence Society, in <i>Neurourol. & Urodynamics</i> 15:313-314 (1996) (Abstract #36)		
	47.	STERNBACH et al., "Antispasmodics. I. Bicyclic Basic Alcohols," <i>J. Amer. Chem. Soc.</i> 74:2215-2218 (1952)		
	48.	THOMAS et al., "Irreversible Effects of 4-Damp Mustard on Muscarinic Receptors <i>In Vivo</i> ," <i>Proc. West Pharmacol. Soc.</i> 35:233-237 (1992)		
	49.	WAELEBROECK et al., "Binding Kinetics of Quinuclidinyl Benzilate and Methylquinuclidinyl Benzilate Enantiomers at Neuronal (M ₁), Cardiac (M ₂), and Pancreatic (M ₃) Muscarinic Receptors," <i>Molecular Pharmacology</i> 40:413-420 (1991)		

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.